MX2008013978A - Metodos y aparatos para identificar el estado de enfermedades utilizando biomarcadores. - Google Patents

Metodos y aparatos para identificar el estado de enfermedades utilizando biomarcadores.

Info

Publication number
MX2008013978A
MX2008013978A MX2008013978A MX2008013978A MX2008013978A MX 2008013978 A MX2008013978 A MX 2008013978A MX 2008013978 A MX2008013978 A MX 2008013978A MX 2008013978 A MX2008013978 A MX 2008013978A MX 2008013978 A MX2008013978 A MX 2008013978A
Authority
MX
Mexico
Prior art keywords
data
biomarker
condition
biomarkers
biomarker data
Prior art date
Application number
MX2008013978A
Other languages
English (en)
Spanish (es)
Inventor
Grimes F Randall
Original Assignee
Provista Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provista Diagnostics Llc filed Critical Provista Diagnostics Llc
Publication of MX2008013978A publication Critical patent/MX2008013978A/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Primary Health Care (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
MX2008013978A 2006-05-01 2007-04-25 Metodos y aparatos para identificar el estado de enfermedades utilizando biomarcadores. MX2008013978A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/381,104 US20070255113A1 (en) 2006-05-01 2006-05-01 Methods and apparatus for identifying disease status using biomarkers
PCT/US2007/067418 WO2007130831A2 (en) 2006-05-01 2007-04-25 Methods and apparatus for identifying disease status using biomarkers

Publications (1)

Publication Number Publication Date
MX2008013978A true MX2008013978A (es) 2009-02-19

Family

ID=38648787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008013978A MX2008013978A (es) 2006-05-01 2007-04-25 Metodos y aparatos para identificar el estado de enfermedades utilizando biomarcadores.

Country Status (13)

Country Link
US (5) US20070255113A1 (https=)
EP (2) EP2016405B1 (https=)
JP (1) JP2009535644A (https=)
KR (1) KR20090024686A (https=)
CN (1) CN101479599A (https=)
AU (1) AU2007248299A1 (https=)
BR (1) BRPI0711148A2 (https=)
CA (1) CA2650872C (https=)
IL (1) IL195054A0 (https=)
MX (1) MX2008013978A (https=)
RU (1) RU2008147223A (https=)
WO (1) WO2007130831A2 (https=)
ZA (1) ZA200809968B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158374B1 (en) 2006-09-05 2012-04-17 Ridge Diagnostics, Inc. Quantitative diagnostic methods using multiple parameters
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US7955822B2 (en) * 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
US8440418B2 (en) 2008-11-18 2013-05-14 Ridge Diagnostics, Inc. Metabolic syndrome and HPA axis biomarkers for major depressive disorder
US20110245092A1 (en) * 2008-03-04 2011-10-06 John Bilello Diagnosing and monitoring depression disorders based on multiple serum biomarker panels
WO2009114627A2 (en) * 2008-03-12 2009-09-17 Ridge Diagnostics, Inc. Inflammatory biomarkers for monitoring depression disorders
ES2665245T3 (es) 2008-08-11 2018-04-25 Banyan Biomarkers, Inc. Proceso de detección de biomarcador y ensayo de estado neurológico
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20140342381A1 (en) * 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
EP2471016A1 (en) * 2009-08-28 2012-07-04 Lexicor Medical Technology, LLC Systems and methods to identify a subgroup of adhd at higher risk for complicating conditions
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
US20150127378A1 (en) * 2012-02-11 2015-05-07 Yougene Corp. Systems for storing, processing and utilizing proprietary genetic information
JP6075973B2 (ja) * 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
EP2684513A1 (en) 2012-07-13 2014-01-15 Universite D'angers Method for providing reliable non-invasive diagnostic tests
WO2014089268A2 (en) 2012-12-06 2014-06-12 StemBios Technologies, Inc. Lgr5+ somatic stem cells
EP2746769A1 (en) * 2012-12-21 2014-06-25 Stembios Technologies, Inc. Method for evaluating effect of action on subject based on stem celldynamics
HK1216765A1 (zh) * 2013-03-14 2016-12-02 奥特拉西斯公司 使用所测分析物改进疾病诊断的方法
US20140275294A1 (en) * 2013-03-15 2014-09-18 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of liver injury
CN103279655A (zh) * 2013-05-20 2013-09-04 浙江大学 一种恶性肿瘤放化疗规范符合度的评估方法
CN105431853B (zh) 2013-05-23 2018-12-28 艾弗诺泰普有限责任公司 表型整合的社会研究数据库和方法
US10190169B2 (en) 2013-06-20 2019-01-29 Immunexpress Pty Ltd Biomarker identification
PL3084664T3 (pl) * 2013-12-16 2020-10-05 Philip Morris Products S.A. Układy i sposoby do przewidywania statusu palenia u osobnika
US11047010B2 (en) 2014-02-06 2021-06-29 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits thereof
JP2017516085A (ja) * 2014-04-08 2017-06-15 メタボルン インコーポレーティッド 疾患診断および健康評価のための個々の対象の低分子生化学プロファイリングの方法
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
AU2016267392B2 (en) * 2015-05-28 2021-12-09 Immunexpress Pty Ltd Validating biomarker measurement
RU2018127709A (ru) * 2016-01-22 2020-02-25 Отрэйсис, Инк. Системы и способы улучшения диагностики заболеваний
US11594311B1 (en) 2016-03-31 2023-02-28 OM1, Inc. Health care information system providing standardized outcome scores across patients
US11957897B2 (en) 2016-04-22 2024-04-16 Newton Howard Biological co-processor (BCP)
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
WO2019183052A1 (en) * 2018-03-19 2019-09-26 Sri International Methods and systems for biomarker analysis
US20190302119A1 (en) * 2018-03-27 2019-10-03 Lawrence Abraham Cancer Diagnostic Metastasis Panel
US11967428B1 (en) * 2018-04-17 2024-04-23 OM1, Inc. Applying predictive models to data representing a history of events
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
LU100835B1 (en) * 2018-06-13 2019-12-13 Univ Muenster Westfaelische Wilhelms Novel biomarkers for recurrent tonsillitis
US11862346B1 (en) 2018-12-22 2024-01-02 OM1, Inc. Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
US20200395097A1 (en) * 2019-05-30 2020-12-17 Tempus Labs, Inc. Pan-cancer model to predict the pd-l1 status of a cancer cell sample using rna expression data and other patient data
TWI740647B (zh) * 2020-09-15 2021-09-21 宏碁股份有限公司 疾病分類方法及疾病分類裝置
US20220223231A1 (en) * 2021-01-14 2022-07-14 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Improved Prognostics in Medical Imaging
KR102671925B1 (ko) * 2022-03-03 2024-06-03 인제대학교 산학협력단 파킨슨병 진단 방법 및 그 시스템

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197532B1 (en) * 1998-01-22 2001-03-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnosis and detection of breast cancer and other cancers
CA2300639A1 (en) * 1999-03-15 2000-09-15 Whitehead Institute For Biomedical Research Methods and apparatus for analyzing gene expression data
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US6714925B1 (en) * 1999-05-01 2004-03-30 Barnhill Technologies, Llc System for identifying patterns in biological data using a distributed network
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US20030087865A1 (en) * 2001-07-13 2003-05-08 Whitehead Institute For Biomedical Research Leukemogenic transcription factors
US20030225526A1 (en) * 2001-11-14 2003-12-04 Golub Todd R. Molecular cancer diagnosis using tumor gene expression signature
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
US20040076974A1 (en) * 2002-04-01 2004-04-22 Kier Larry D. Liver necrosis predictive genes
US20050176057A1 (en) * 2003-09-26 2005-08-11 Troy Bremer Diagnostic markers of mood disorders and methods of use thereof

Also Published As

Publication number Publication date
EP2016405A2 (en) 2009-01-21
US20110077931A1 (en) 2011-03-31
CA2650872C (en) 2018-04-24
BRPI0711148A2 (pt) 2011-08-23
EP2016405A4 (en) 2012-10-03
US20070254369A1 (en) 2007-11-01
EP2016405B1 (en) 2017-09-27
KR20090024686A (ko) 2009-03-09
CN101479599A (zh) 2009-07-08
AU2007248299A1 (en) 2007-11-15
EP3318995A1 (en) 2018-05-09
US20070255113A1 (en) 2007-11-01
CA2650872A1 (en) 2007-11-15
ZA200809968B (en) 2009-08-26
US20210041440A1 (en) 2021-02-11
IL195054A0 (en) 2009-08-03
JP2009535644A (ja) 2009-10-01
WO2007130831A2 (en) 2007-11-15
US20130060549A1 (en) 2013-03-07
WO2007130831A3 (en) 2008-10-30
RU2008147223A (ru) 2010-06-10

Similar Documents

Publication Publication Date Title
US20210041440A1 (en) Methods and apparatus for identifying disease status using biomarkers
Maas et al. Predicting outcome after traumatic brain injury
Whiting et al. Development and validation of methods for assessing the quality of diagnostic accuracy studies
US11885733B2 (en) White blood cell population dynamics
US20190324036A1 (en) Panels for testing for sepsis
Kureshi et al. Association between cardiac rehabilitation participation and health status outcomes after acute myocardial infarction
Whitlatch et al. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia
US20230215571A1 (en) Automated classification of immunophenotypes represented in flow cytometry data
Janes et al. Matching in studies of classification accuracy: implications for analysis, efficiency, and assessment of incremental value
Darooei et al. Discriminating tuberculous pleural effusion from malignant pleural effusion based on routine pleural fluid biomarkers, using mathematical methods
Murphy Longitudinal studies 1: Determinants of risk
JP2016201123A (ja) 動的ネットワークバイオマーカーの検出装置、検出方法及び検出プログラム
Varadhan et al. Review of guidance documents for selected methods in patient centered outcomes research: standards in addressing heterogeneity of treatment effectiveness in observational and experimental patient centered outcomes research
Ma et al. Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study
He et al. Prediction models for postoperative pneumonia in elderly hip fracture patients: a systematic review and critical appraisal
EP3203911A1 (en) Personalized antibiotic dosing platform
CN121002198A (zh) 用于鉴别一种或多种预测性生物标志物的人工智能
Goldman et al. Facility characteristics do not explain higher false-positive rates in diagnostic mammography at facilities serving vulnerable women
Daya Characteristics of good causation studies
Comino et al. Machine Learning-Based Assessment Indicates Patient-Reported Outcomes to Be Less Reliable than Clinical Parameters for Predicting 1-Year Survival in Cancer Patients.
Comino et al. Article Not peer-reviewed version
Murphy Longitudinal studies 1: determination of risk
Deng et al. Introduction to the development and validation of predictive biomarker models from high-throughput data sets
Rogers et al. Evaluating the utility and challenges associated with" anonymous" patients in the electronic medical record
Mayer et al. Enhancing Phenotype Discovery in Electronic Health Records through Prior Knowledge-Guided Unsupervised Learning

Legal Events

Date Code Title Description
FA Abandonment or withdrawal